Aravive Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Aravive's earnings have been declining at an average annual rate of -12.3%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been declining at an average rate of 6.2% per year.
Información clave
-12.3%
Tasa de crecimiento de los beneficios
29.7%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | 17.0% |
Tasa de crecimiento de los ingresos | -6.2% |
Rentabilidad financiera | -2,342.6% |
Margen neto | -569.7% |
Última actualización de beneficios | 30 Sep 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely
Apr 26Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely
Sep 03Aravive Q2 GAAP EPS misses, revenue beats
Aug 11Aravive appoints Robert Geller as CMO
Jul 05We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully
May 15Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Nov 06Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Jun 25Aravive EPS beats by $0.01, misses on revenue
May 06Aravive shares rise after dosing first patient in late-stage ovarian cancer study
Apr 27Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?
Mar 18Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Feb 09Aravive: Pipeline-In-A-Pill In Oncology
Dec 28Aravive (ARAV) Investor Presentation - Slideshow
Dec 04Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative
Nov 19Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China
Nov 10Desglose de ingresos y gastos
Cómo gana y gasta dinero Aravive. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Sep 23 | 7 | -40 | 13 | 0 |
30 Jun 23 | 9 | -77 | 13 | 0 |
31 Mar 23 | 10 | -113 | 13 | 0 |
31 Dec 22 | 9 | -76 | 13 | 0 |
30 Sep 22 | 9 | -60 | 12 | 0 |
30 Jun 22 | 6 | -56 | 12 | 0 |
31 Mar 22 | 8 | -44 | 11 | 0 |
31 Dec 21 | 7 | -39 | 11 | 0 |
30 Sep 21 | 12 | -30 | 11 | 0 |
30 Jun 21 | 10 | -30 | 11 | 0 |
31 Mar 21 | 6 | -28 | 11 | 0 |
31 Dec 20 | 6 | -31 | 13 | 0 |
30 Sep 20 | 0 | -31 | 13 | 0 |
30 Jun 20 | 0 | -26 | 13 | 0 |
31 Mar 20 | 3 | -24 | 13 | 0 |
31 Dec 19 | 5 | -18 | 14 | 0 |
30 Sep 19 | 6 | -65 | 21 | 0 |
30 Jun 19 | 6 | -65 | 23 | 0 |
31 Mar 19 | 3 | -72 | 25 | 0 |
31 Dec 18 | 1 | -76 | 26 | 0 |
30 Sep 18 | 40 | 6 | 23 | -93 |
30 Jun 18 | 40 | -37 | 25 | -51 |
31 Mar 18 | 40 | -64 | 26 | -22 |
31 Dec 17 | 40 | -85 | 29 | 0 |
30 Sep 17 | 0 | -138 | 28 | 110 |
30 Jun 17 | 0 | -116 | 28 | 88 |
31 Mar 17 | 0 | -101 | 26 | 76 |
31 Dec 16 | 0 | -96 | 24 | 72 |
30 Sep 16 | 0 | -94 | 21 | 71 |
30 Jun 16 | 0 | -87 | 22 | 66 |
31 Mar 16 | 0 | -84 | 21 | 61 |
31 Dec 15 | 0 | -82 | 20 | 60 |
30 Sep 15 | 0 | -78 | 22 | 56 |
30 Jun 15 | 0 | -71 | 18 | 51 |
31 Mar 15 | 0 | -60 | 16 | 45 |
31 Dec 14 | 0 | -83 | 14 | 33 |
30 Sep 14 | 0 | -73 | 12 | 24 |
30 Jun 14 | 0 | -64 | 9 | 19 |
31 Mar 14 | 0 | -59 | 6 | 16 |
31 Dec 13 | 0 | -18 | 4 | 15 |
Ingresos de calidad: ARAV is currently unprofitable.
Margen de beneficios creciente: ARAV is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: ARAV is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.
Acelerando crecimiento: Unable to compare ARAV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: ARAV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Rentabilidad financiera
Alta ROE: ARAV has a negative Return on Equity (-2342.56%), as it is currently unprofitable.